Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.55 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.46 |
| ▸ | IGF1R | P08069 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.42 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.42 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6991230 | 0.88 | CA2 (0.52) | CA2CYP4A11ALDH1A1KMT2AMEN1 | |
| SCHEMBL80441 | 0.88 | IGF1R (0.55) | CA2CYP4A11CYP4F2IGF1RALOX15 | |
| SCHEMBL3540843 | 0.86 | CA2 (0.56) | CA2CYP4A11ALDH1A1KMT2AMEN1 | |
| SCHEMBL5108050 | 0.83 | L3MBTL1 (0.54) | CA2CYP4A11ALDH1A1KMT2AMEN1 | |
| SCHEMBL27557738 | 0.83 | CA2 (0.53) | CA2CYP4A11CYP4F2TAAR1 | |
| Hydrocinnamyl Alcohol SCHEMBL28034182 | 0.82 | POLB (0.59) | CA2CYP4A11ALDH1A1KMT2AMEN1 | |
| Sulfuric Acid SCHEMBL11590005 | 0.82 | IGF1R (0.55) | CA2ALDH1A1KMT2AMEN1IGF1R | |
| SCHEMBL285785 | 0.81 | IGF1R (0.59) | CA2CYP4A11ALDH1A1CYP4F2IGF1R | |
| Toluene SCHEMBL10896125 | 0.80 | LTA4H (0.53) | CA2CYP4A11ALDH1A1IGF1RALOX15 | |
| Hexane SCHEMBL9492419 | 0.80 | ALDH1A1 (0.53) | CA2ALDH1A1KMT2AMEN1IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017646-B2 | e.g. 1-{3-[3-(3,4-dimethoxyphenyl)propoxy]propyl}pyrrolidine; neurodegenerative disorders, antidepressant, antidiabetic, hypotensive agent, cognition activator; | BIOPROJET (FR) | 2011-09-13 | — | — | US | disclosed |
| US-20080182876-A1 | Histamine H3-Receptor Ligands and Their Therapeutic Application | BIOPROJET (FR) | 2008-07-31 | — | — | US | disclosed |
| EP-1874747-A1 | HISTAMINE H3-RECEPT0R LIGANDS AND THEIR THERAPEUTIC APPLICATION | BIOPROJET (FR) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006117611-A1 | HISTAMINE H3-RECEPT0R LIGANDS AND THEIR THERAPEUTIC APPLICATION | BIOPROJET (FR) | 2006-11-09 | — | — | WO | disclosed |
| EP-1717233-A1 | Histamine H3-receptor ligands and their therapeutic application | BIOPROJET (FR) | 2006-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182876-A1 | Histamine H3-Receptor Ligands and Their Therapeutic Application | HRH3, HRH4, HRH1 | CA2 1812/4885CYP4A11 1141/4885ALDH1A1 1327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.